US · ICCC
ImmuCell Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Portland, ME 04103
- Website
- immucell.com
Price · as of 2024-12-31
$8.73
Market cap 59.43M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $221.52 | +2,437.46% |
| Intrinsic Value(DCF) | $2.04 | -76.63% |
| Graham-Dodd Method(GD) | $2.04 | -76.67% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $3.12 | $118.56 | $1.80 | $2.48 | $0.00 |
| 2011 | $4.70 | $508.28 | $1.75 | $2.34 | $0.00 |
| 2012 | $3.70 | $4,404.16 | $1.95 | $3.19 | $0.39 |
| 2013 | $4.83 | $79.39 | $1.38 | $3.31 | $0.74 |
| 2014 | $6.85 | $387.62 | $10.45 | $2.78 | $0.00 |
| 2015 | $6.32 | $187.17 | $63.47 | $5.48 | $16.44 |
| 2016 | $5.32 | $401.69 | $10.07 | $5.25 | $0.22 |
| 2017 | $7.27 | $1,251.75 | $6.61 | $4.58 | $0.00 |
| 2018 | $6.81 | $438.31 | $1.49 | $1.83 | $0.00 |
| 2019 | $4.98 | $392.63 | $4.10 | $3.29 | $0.00 |
| 2020 | $10.77 | $69.81 | $3.22 | $3.20 | $0.00 |
| 2021 | $8.75 | $72.73 | $14.73 | $4.23 | $0.00 |
| 2022 | $5.49 | $667.84 | $0.91 | $2.30 | $0.00 |
| 2023 | $5.20 | $56.70 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.11 | $221.52 | $11.95 | $2.04 | $0.00 |
AI valuation
Our deep-learning model estimates ImmuCell Corporation's (ICCC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $221.52
- Current price
- $8.73
- AI upside
- +2,437.46%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.04
-76.63% upside
Graham-Dodd
$2.04
-76.67% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ICCC | ImmuCell Corporation | $8.73 | 59.43M | +2,437% | -77% | -77% | — | -19.35 | 1.52 | 1.58 | 49.76 | — | 1.52 | 29.97% | -6.19% | -8.14% | -8.22% | -4.12% | -4.85% | 0.55 | -2.88 | 3.41 | 1.72 | 10.63 | -6533.00% | 5164.00% | -9836.00% | -0.26% | 0.08 | -0.27% | 0.00% | 0.00% | 10.47% | -32.36 | -492.25 | 2.00 | 1.73 |
| COEP | Coeptis Therapeutics, Inc… | $12.04 | 42.29M | — | — | — | — | -1.87 | 6.40 | — | -2.25 | -0.32 | 7.72 | 0.00% | — | — | -290.10% | -247.64% | -128.12% | 0.44 | -25.38 | 0.23 | 0.12 | -0.09 | 58072.00% | — | -815.00% | -32.60% | -1.47 | -163.77% | 0.00% | 0.00% | 0.00% | -2.11 | -3.20 | — | -17.20 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| EQ | Equillium, Inc. | $1.82 | 64.65M | +1,406% | -79% | — | — | -3.51 | 1.48 | 0.69 | -0.81 | — | 1.48 | 100.00% | -20.12% | -19.63% | -38.75% | 80.29% | -21.19% | 0.02 | — | 3.93 | 3.73 | 2.34 | -3947.00% | 1389.00% | -1247.00% | -67.56% | -2.99 | 185.55% | 0.00% | 0.00% | 0.00% | -0.74 | -0.32 | 0.15 | -6.59 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| GNTA | Genenta Science S.p.A. | $0.99 | 18.96M | — | — | — | — | -6.66 | 4.75 | — | -4.80 | — | 4.78 | 0.00% | — | — | -54.13% | -1295.77% | -47.95% | 0.00 | — | 6.89 | 6.72 | 0.47 | -2344.00% | — | -4434.00% | -10.53% | -2.97 | -828.69% | 0.00% | 0.00% | 1.48% | -4.78 | -7.48 | — | 8.82 |
| IPSC | Century Therapeutics, Inc… | $2.32 | 202.78M | +1,581% | -88% | — | — | -0.41 | 0.32 | 7.82 | 0.75 | — | 0.41 | 100.00% | -2096.48% | -1920.87% | -73.14% | -320.94% | -35.46% | 0.33 | — | 1.50 | 1.47 | 0.04 | -3000.00% | 19481.00% | 804.00% | -214.09% | -0.85 | -256.24% | 0.00% | 0.00% | 10.59% | 0.61 | 0.76 | -12.74 | -3.99 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SNTI | Senti Biosciences, Inc. | $0.94 | 24.82M | +2,578% | — | — | — | -0.31 | 0.63 | — | -0.03 | — | 0.63 | 0.00% | — | — | -114.06% | -153.24% | -48.58% | 1.31 | — | 4.49 | 3.81 | 0.27 | -4513.00% | -10000.00% | -3571.00% | -256.05% | -3.15 | -103.99% | 0.00% | 0.00% | 101.22% | -0.03 | -0.04 | — | -5.61 |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
- CEO
- F. Olivier Te Boekhorst
- Employees
- 69
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.04 ÷ $8.73) − 1 = -76.63% (DCF, example).